Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Interest & Investment Income (2017 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Interest & Investment Income for 12 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 231.07% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, up 69.57% year-over-year, with the annual reading at $13.7 million for FY2025, 69.57% up from the prior year.
  • Interest & Investment Income hit $6.4 million in Q4 2025 for Ligand Pharmaceuticals, up from $3.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $6.4 million in Q4 2025 to a low of $134000.0 in Q1 2022.
  • Historically, Interest & Investment Income has averaged $1.6 million across 5 years, with a median of $1.5 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: crashed 93.74% in 2021 and later surged 970.9% in 2023.
  • Year by year, Interest & Investment Income stood at $188000.0 in 2021, then soared by 444.15% to $1.0 million in 2022, then skyrocketed by 65.49% to $1.7 million in 2023, then rose by 14.06% to $1.9 million in 2024, then surged by 231.07% to $6.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for LGNDZ at $6.4 million in Q4 2025, $3.9 million in Q3 2025, and $1.6 million in Q2 2025.